Scleroderma: Cyclophosphamide or Transplantation (SCOT) Substudy 01. The primary purpose of this study is to determine the plasma concentration and exposure time required for cyclosphosphamide to produce optimal immunosuppressive activity with minimal toxicity in subjects with severe systemic sclerosis. This study is currently enrolling participants by invitation only. ClinicalTrials.gov. 02/19/09. (Also see: Clinical Trials)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Scleroderma: Cyclophosphamide or Transplantation
No replies to this topic